TP53 and central nervous system leukemia: 2–14 years (61 patients) and 15–61 years (39 patients)R/R B-ALL, including high-risk features: BCR-ABLfusion gene, TP53 mutation (12), extramedullary disease (including patients with central nervous system leukemia), and relapses after allogeneic stem cell transplantation (16)